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Background: For the past 30 years, opioids have been used to treat chronic nonmalignant pain. 
This study tests the following hypotheses: (1) there is no strong evidence-based foundation for 
the conclusion that long-term opioid treatment of chronic nonmalignant pain is effective; and 
(2) the main problem associated with the safety of such treatment – assessment of the risk of 
addiction – has been neglected.
Methods: Scientometric analysis of the articles representing clinical research in this area was 
performed to assess (1) the quality of presented evidence (type of study); and (2) the duration 
of the treatment phase. The sufficiency of representation of addiction was assessed by counting 
the number of articles that represent (1) editorials; (2) articles in the top specialty journals; and 
(3) articles with titles clearly indicating that the addiction-related safety is involved (topic-in-
title articles).
Results: Not a single randomized controlled trial with opioid treatment lasting .3 months 
was found. All studies with a duration of opioid treatment $6 months (n = 16) were conducted 
without a proper control group. Such studies cannot provide the consistent good-quality 
evidence necessary for a strong clinical recommendation. There were profound differences 
in the number of addiction articles related specifically to chronic nonmalignant pain patients 
and to opioid addiction in general. An inadequate number of chronic pain-related publications 
were observed with all three types of counted articles: editorials, articles in the top specialty 
journals, and topic-in-title articles.
Conclusion: There is no strong evidence-based foundation for the conclusion that long-term 
opioid treatment of chronic nonmalignant pain is effective. The above identified signs indicat-
ing neglect of addiction associated with the opioid treatment of chronic nonmalignant pain 
were present.
Keywords: addiction, chronic pain, neuropathic pain, opioids, overdose death, quality of 
evidence, treatment efficacy
Introduction
Only relatively recently in the history of medicine, was there a need to demonstrate 
quality of evidence and strength of recommendations to validate treatment 
effectiveness.1–3 Such support has been provided for various treatments of acute pain 
with opioids.4 Opiates have been used for treatment of acute and persistent pain for 
centuries, before the current standards of evidence quality became the norm. Compared 
to this, the treatment of chronic nonmalignant pain with opioids is a relatively new 
development. For the period 1983–2012, PubMed has more than 2,000 articles on the 
opioid treatment of chronic nonmalignant pain, but almost no articles on this topic 
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before then. In regards to the Bonica pain clinic treatment 
practices from 1960–1980, Loeser wrote that
“it did not enter our minds that there could be a significant 
number of chronic pain patients who were successfully 
managed with opioids, because if there were any, we almost 
never saw them.”5
This explains the almost complete absence of publications 
on the opioid treatment of chronic pain before 1983. The 
value of opioids in the treatment of chronic pain attribut-
able to cancer was well recognized before the 1980s. As far 
as nonmalignant chronic pain is concerned, several initial 
publications were collected and summarized in the mid-
1980s.12 The use of opioids for chronic pain management 
was introduced when the new standards of evidence-based 
medicine were already in the final stages of their establish-
ment. Despite this, the opioid treatment of chronic pain came 
into practice without convincing proof of effectiveness. Since 
then, doubts about the effectiveness and safety of long-term 
treatment of chronic nonmalignant pain with opioids have 
been expressed in several reviews.6–9
The goal of the present study was to test the following 
hypotheses: (1) there is no strong evidence-based foundation 
for the conclusion that long-term opioid treatment of chronic 
nonmalignant pain is effective; and (2) the risk of addiction – 
the main problem associated with the safety of such treatment – 
has been neglected. The available information pertinent to these 
hypotheses was analyzed using scientometric approaches.
Methods
The articles were collected mainly using the National Library 
of Medicine’s PubMed website (http://www.ncbi.nlm.nih.
gov/PubMed). Articles published in English over the 30-year 
period of 1983–2012 were included. Keywords related to 
chronic pain (“chronic pain” OR “neuropathic pain”) were 
added to the terms related to opioids (“opioids” OR “narcotic 
analgesics” OR “morphine”). In addition, cancer pain and 
terminal illness were excluded from the search by placing in the 
search box the following: NOT (“cancer pain” OR “terminal 
illness”). Boolean operations were used, in which the following 
variables were selected: keywords, years of publications, and 
type of publications. In addition to the electronic search of 
articles, related publications were also searched manually in 
the reference lists of reports and reviews.
Efficacy hypothesis
Articles found in the searches were reviewed to make sure 
that they fit the definition of chronic pain. Articles with titles 
that lacked certain indication of pain duration, such as “persis-
tent,” “persisting,” or “long-term” were checked and included 
in the database only if the duration of pain was $3 months. 
Criteria for excluding articles were: (1) inclusions of cases 
with malignant pain; (2) inclusions of treatments combining 
opioids with local anesthetics or antidepressants; (3) duration 
of treatment of 1 day (or ,24 hours); and (4) having fewer than 
ten patients.4 To assess the quality of evidence for the efficacy 
for the treatment, the following factors were taken into con-
sideration: the type of the study (randomized controlled trial 
[RCT] or not), the duration of opioid treatment ($6 months 
or not), and the study conclusion on the treatment efficacy.
Addiction hypothesis
The following signs were used to determine whether attention 
to the addiction-related safety of long-term opioid treatment 
was insufficient: the number of journal editorials on this topic, 
the number of articles in the top specialty journals, and the 
number of journal articles with titles clearly stating that the 
addiction-related safety of the treatment is involved. The edi-
torials (articles solicited by an editorial board to provide an 
editorial perspective on an article published in a journal) on 
several topics associated with the safety of long-term opioid 
treatment of chronic pain were selected in the following 
way: keywords related to chronic pain (“chronic pain” OR 
“neuropathic pain”) and opioids (“opioids” OR “narcotic 
analgesics” OR “morphine”) were combined with keywords 
associated with addiction (“addiction” OR “dependence” OR 
“abuse” OR “misuse”) or with overdose death (“death” OR 
“mortality” OR “fatality”). The article type was selected by 
using the PubMed filtering tool “Editorial.”
To quantitatively evaluate the presentation of the above 
topics in leading medical journals, the 20 top journals were 
selected with the approach used previously.10 The journal 
selection was based on two factors: (1) the rank of a journal 
sorted by the impact factor, as indicated by Journal Citation 
Report for 2011 (http://science.thomsonreuter.com) and 
(2) the journal specialty area. They included biomedical 
journals in general (ten journals), pharmacology (six 
journals), and psychiatry or neurology (four journals). 
The impact factor was used for the selection of journals 
in each specialty area category separately. The following 
journals were included: Addiction, The American Journal 
of Psychiatry, Annals of Internal Medicine, Annals 
of Neurology, Archives of General Psychiatry, BMJ, 
The Journal of Clinical Investigation, The Journal of 
Pharmacology and Experimental Therapeutics, JAMA: 
The Journal of the American Medical Association, Lancet, 
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The New England Journal of Medicine, Nature Medicine, 
Nature Neuroscience, Nature Reviews Drug Discovery, 
Nature Reviews Neuroscience, Nature, Pharmacological 
Reviews, Proceedings of the National Academy of Science 
of the United States of America, Science (New York, NY, 
USA), and Trends in Pharmacological Sciences. All types 
of articles were used for this index.
To select articles with titles clearly indicating that they 
are devoted to specific topics (topic-in-title articles), the 
indicator “(Title)” was added to the selected terms placed 
into PubMed search boxes. All types of articles were used 
for this index also.
Results
Efficacy hypothesis
The electronic and manual search of the literature identified 
2,356 articles. The results of this initial search were reviewed 
and reduced to 250 articles; see flowchart (Figure 1) and 
Supplementary material. Fifty-three articles were original 
clinical research articles on the opioid treatment of chronic 
nonmalignant pain (Table 1).11–63 Analysis of these publica-
tions revealed that 25 are reports of RCT studies, the rest 
are studies that lack a proper control group.64 Most of the 
RCT studies had a treatment duration of #1 month. Only 
one study is in the “$3 months category” (90 days).58 The 
other randomized investigation with long treatment duration 
(16 weeks) was an open study.65 Table 2 presents 16 studies in 
which the duration of opioid treatment was $6 months, none 
of which is an RCT. Thus, there is not a single study that both 
fits the high quality of evidence category and has a long-term 
opioid treatment (duration of treatment $6 months). System-
atic reviews on the opioid treatment of chronic nonmalignant 
pain have come to the same conclusion regarding long-term 
efficacy of the treatment, ie, there is insufficient evidence to 
make a definite conclusion (Table 3).6–9
Addiction hypothesis
The results on the editorials related to addiction in chronic 
nonmalignant pain patients are presented in Table 4. There 
were no editorials on this topic in 1983–1992, one in 
Potentially relevant 1983–2012
articles identified through
Medline and other sources
(n = 2,356)
Articles excluded
(n = 2,106)
Articles relevant to
chronic nonmalignant pain
(n = 250)
Original clinical research studies
(n = 53)
Treatment duration Treatment duration
RCT
(n = 25)
Non-RCT
(n = 28)
<3 months
(n = 10)
<3 months
(n = 24)
>6 months
(n = 13)
>6 months
(n = 0)
3–6 months
(n = 5)
3–6 months
(n = 1)
Case reports (<10),
reviews, editorials,
comments, letters
(n = 197)
Figure 1 Flow chart of screened, excluded, and included articles on chronic nonmalignant pain from 1983–2012.
Abbreviation: RCT, randomized con  trolled trial.
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Table 1 Duration of opioid treatment in studies on chronic nonmalignant pain
Duration of treatment Number of studies without a proper control  
group*,11–38
Number of randomized controlled trials39–63
#1 m .1 m–,3 m $3 m $1 y #1 m .1 m–,3 m $3 m #1 y
Years
  1983–1992 1 0 0 3 1 0 0 0
  1993–2002 4 1 2 6 10 2 0 0
  2003–2012 4 0 3 4 5 6 1 0
  Total 9 1 5 13 16 8 1 0
Note: *Studies without a proper control group (see Grimes and Schulz).64
Abbreviations: m, month; y, year.
1993–2002, and four in 2003–2012. For the same period, 
editorials on opioid addiction in general (the right side of 
Table 4) were numerous (171 from 2003–2012). As far 
as editorials on death associated with opioid treatment of 
chronic nonmalignant pain are concerned, only two were 
found – both recent – in 2010–2011.67,69
Representation of opioid addiction in the top 20 journals 
is shown in Table 5 (left side – opioid addiction in patients 
with chronic pain; right side – opioid addiction in general). 
Once again, the problem of opioid addiction in chronic pain 
patients was discussed in only six articles (five of which 
appeared in 2003–2012). The problem of death associated 
with opioid treatment of chronic pain was discussed only in 
three articles from the top journals.71,72,77
The topic-in-title articles (articles clearly announcing that 
they are devoted to opioid addiction, dependence, abuse, or 
misuse) are presented in Table 6. The right side of the table 
presents the articles on addiction-related problems in general, 
and the left side presents those specifically in chronic pain 
patients. It indicates that in 1983–1992 only two topic-in-title 
articles related to opioid addiction in chronic pain patients 
were published; in the next 10-year period, this number 
increased to 13; and was 51 for 2003–2012. It is of interest 
that in the 15 years following 1983, the word “addiction” in 
titles appeared only once; the word “abuse” was used in the 
rest of the article titles. On the other hand, topic-in-title articles 
on addiction-related problems in general (the right side of 
Table 6) were numerous (1,404 in 2003–2012). It is of inter-
est that during 1983–2002 when opioids were introduced for 
the treatment of chronic nonmalignant pain, there was a clear 
decrease in the number of articles devoted to the problem of 
opioid addiction in general (from 893 in 1973–1982 to 536 
and 628 in 1983–1992 and 1993–2002, respectively).
Topic-in-title articles on death associated with opioid 
addiction in chronic pain patients are presented in Table 7. 
This table indicates only four such articles, all in 2003–2012. 
Topic-in-title articles on death associated with opioid 
addiction in general (the right side of Table 7) were also very 
rare (two to four articles per decade).
Discussion
Efficacy hypothesis
Simple scientometric assessment of articles on long-term 
opioid treatment of chronic nonmalignant pain indicates the 
absence of high-quality evidence on efficacy. There is not a 
single RCT study lasting .3 months (Table 1). The longest 
randomized investigation (16 weeks) was limited by being 
an open study.65 All studies with opioid treatment $6 months 
(Table 2) were conducted without a proper control group;64 
therefore, they do not provide the consistent good-quality 
evidence to support a strong clinical recommendation.1–3 
Systematic reviews on opioid treatment of chronic nonmalig-
nant pain have concluded that there is insufficient evidence 
to make a definite conclusion on the efficacy of long-term 
treatment.6–9
Addiction hypothesis
The problem of safety of opioid treatment revealed itself most 
dramatically in rising numbers of opioid overdose deaths. 
According to the 2008 National Survey on Drug Use and 
Health (NSDUH) sponsored by the Substance Abuse and 
Mental Health Service Administration (SAMHSA), there has 
been at least a ten-fold increase in the medical use of opioids 
from 1988–2007.149 In 2007, 11,499 deaths were caused by 
overdoses of opioids, roughly a four-fold increase compared 
with 1999. Remarkably, even an increase of that size some-
how did not trigger a timely response by the medical journals. 
This phenomenon is especially noticeable if one looks at the 
number of editorials on death associated with opioid treatment 
of chronic pain patients. Only two editorials on this topic 
were found (both late, in 2010–2011), as if there had been no 
dramatic increase in opioid-related deaths in 1999–2007.
Opioid abuse, misuse, and addiction are the main 
reasons leading to the opioid overdose deaths. Somehow the 
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. Table 4 Editorials on opioid addiction in chronic pain patients
Years Number of editorials
“Addiction”a AND 
“chronic pain”b
“Addiction”a
1973–1982 – 12
1983–1992 0 19
1993–2002 1c 63
2003–2012 4d 171
Notes: aOR “dependence” OR “abuse” OR “misuse;” bOR “neuropathic pain” NOT 
(“cancer pain” OR “terminal illness”); creference 66; dreferences 67–70.
Table 5 Articles on opioid addiction in chronic pain patients in 
the top 20 journalsa
Years Number of articles
“Addiction”b AND 
“chronic pain”c
“Addiction”b
1973–1982 – 5
1983–1992 1d 5
1993–2002 0 12
2003–2012 5e 40
Notes: aList of top journals: Addiction, The American Journal of Psychiatry, Annals of 
Internal Medicine, Annals of Neurology, Archives of General Psychiatry, BMJ, The Journal of 
Clinical Investigation, The Journal of Pharmacology and Experimental Therapeutics, JAMA: 
The Journal of the American Medical Association, Lancet, The New England Journal of 
Medicine, Nature Medicine, Nature Neuroscience, Nature Reviews Drug Discovery, Nature 
Reviews  Neuroscience,  Nature,  Pharmacological  Reviews,  Proceedings  of  the  National 
Academy of Science of the United States of America, Science (New York, NY, USA), 
and Trends in Pharmacological Sciences; bOR “dependence” OR “abuse” OR “misuse;” 
cOR “neuropathic pain” NOT (“cancer pain” OR “terminal illness”); dreference 73; 
ereferences 74–78.
introduction of opioid treatment of chronic nonmalignant 
pain did not result in editorials on opioid addiction in chronic 
pain patients: there were five editorials related to this topic, 
four of them published only in 2003–2012. Compare this 
with 171 editorials on opioid addiction in general published 
during this period (Table 4).
Representation for all types of articles (including letters 
and commentaries) on opioid addiction in the top 20 journals 
was also insufficient: zero articles in 1993–2002 (10–15 years 
after the introduction of treatment) and five in 2003–2012 
(Table 5).
The topic-in-title articles clearly announce the topic under 
discussion; however, if the topic is an undesirable problem, 
authors often try to avoid naming it explicitly in the title. The 
lack of topic-in-title publications indicates that the topic is 
a neglected one.150 As indicated in the results of the present 
study, death associated with opioid addiction in chronic 
pain patients was not reflected in titles from 1983–2002; in 
2003–2012, it was found in the titles of only four articles 
(Table 7). This tendency also applied to addiction, abuse, 
misuse, or dependence in opioid treatment of chronic pain. In 
1983–1992, there were only two topic-in-title articles related 
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to opioid addiction in chronic pain patients, at a time when 
there were 536 topic-in-title articles on opioid addiction in 
general (right side of Table 6). There were also profound 
differences in the numbers of addiction articles related 
specifically to chronic pain patients and to opioid addic-
tion in general for the periods 1993–2002 and 2003–2012. 
Especially interesting was the decrease in the number of 
topic-in-title articles on opioid addiction in general during 
1983–2002 (right side of Table 6) when opioid treatment 
for chronic nonmalignant pain was being introduced. Could 
the acceptance of this new indication for opioid treatment 
be responsible for such a change?
Estimates of the rate of addiction problems among chronic 
pain patients extremely varied. Hojsted and Sjogren reported 
that the rates of addiction associated with long-term opioid 
treatment were 0%–50% in noncancer patients and 0%–7.7% 
in cancer patients, depending on the subpopulation studied 
and the criteria used.108 This uncertainty is similar to that with 
the rate of iatrogenic addiction in patients treated with opioids 
for acute or subacute pain. A systematic review on this topic 
concluded, “It is not known whether the risk for iatrogenic 
addiction among patients treated with opioids for acute or 
subacute pain is relatively high (.10%) or low (0.1%).”151 
The difficulty of estimating the risk of opioid addiction and 
abuse (see Jamison et al)152 calls into question the accuracy 
of reported rates of risk for opioid addiction.
One author of a study on the use of opioids in chronic 
nonmalignant pain has asked: “Is this treatment a life-
time sentence?”153 If not, another question should be: 
“Has the withdrawal syndrome after long-term opioid use 
been adequately studied?”; and not only acute withdrawal 
syndrome, but protracted withdrawal as well? The latter 
(also called protracted abstinence or chronic withdrawal 
syndrome) is characterized by generalized symptoms (eg, 
discomfort, fatigue, decreased blood pressure, pulse rate, 
and body temperature) lasting 3–9 months.154–156 Long-lasting 
(3–4 months) neurobiological alterations following 
withdrawal from opioids have been well confirmed in animal 
experiments.157 Lack of knowledge regarding the risk of 
addiction and even greater uncertainty regarding protracted 
withdrawal following cessation of long-term opioid treatment 
of chronic pain call for studies with high-quality evidence 
that supports reliable recommendations.
This study has a limitation related to the absence of exact 
definition of chronic nonmalignant pain. It is associated 
with the lack of definition for chronic pain in general. For 
example, the International Association for the Study of Pain 
Task Force on Taxonomy – in the classification of chronic 
pain – has chosen not to define chronic pain.158
Conclusion
There is no high-quality evidence on the efficacy of long-
term opioid treatment of chronic nonmalignant pain. As a 
result, the strength of any recommendation regarding this 
treatment is weak. The safety of opioid treatment in terms 
of risk of addiction and overdose death has not properly 
been assessed due to the complexity of these outcomes. 
Until 2003, opioid addiction associated with the treatment of 
chronic nonmalignant pain was clearly a neglected topic of 
publication. However, this topic is now beginning to receive 
the attention it deserves.
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